{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:57:40Z","timestamp":1780959460460,"version":"3.54.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"23","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21H04805"],"award-info":[{"award-number":["JP21H04805"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22KJ0806"],"award-info":[{"award-number":["JP22KJ0806"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K19194"],"award-info":[{"award-number":["JP24K19194"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H03708"],"award-info":[{"award-number":["JP20H03708"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K16299"],"award-info":[{"award-number":["JP22K16299"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ama121020"],"award-info":[{"award-number":["JP23ama121020"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Ecotropic viral integration site 1 (EVI1) is essential for hematopoietic stem cell maintenance, and its aberrant expression is a significant adverse prognostic indicator in myeloid leukemia. EVI1 overexpression typically occurs due to chromosomal rearrangement involving 3q26. However, aberrant EVI1 expression is still observed in numerous cases without 3q26 abnormalities, leading to similarly poor outcomes, while the mechanism behind EVI1 overexpression in these cases remains largely unknown. Here, we performed genome-wide CRISPR screening using cells with GFP knock-in at the\n                    <jats:italic>EVI1<\/jats:italic>\n                    locus and identified zinc finger protein 91 (ZFP91) was the leading activator of EVI1. ZFP91 knockout significantly reduced EVI1 expression and cell proliferation. We also showed that ZFP91 binds to the\n                    <jats:italic>EVI1<\/jats:italic>\n                    promoter, enhancing H3K4me3\/H3K27ac and chromatin accessibility. Our data showed that the ZFP91\u2013EVI1 axis plays a critical role for activation of EVI1 in myeloid leukemia. Our screening approach represents a powerful and unbiased method for identifying expression regulators that can be broadly applied across a range of contexts.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03727-7","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:03:26Z","timestamp":1777111406000},"page":"2237-2248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genome-wide screening identifies ZFP91 as a key regulator of EVI1 in myeloid leukemia"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6324-7916","authenticated-orcid":false,"given":"Hiroki","family":"Hayashida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8168-6459","authenticated-orcid":false,"given":"Yosuke","family":"Masamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiya","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Fujiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3019-5817","authenticated-orcid":false,"given":"Ryuichiro","family":"Nakato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Shirahige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4034-2422","authenticated-orcid":false,"given":"Mineo","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"3727_CR1","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/jha2.466","volume":"3","author":"DDH Kim","year":"2022","unstructured":"Kim DDH, Novitzky Basso I, Kim TS, Yi SY, Kim KH, Murphy T, et al. The 17-gene stemness score associates with relapse risk and long-term outcomes following allogeneic haematopoietic cell transplantation in acute myeloid leukaemia. EJHaem. 2022;3:873\u201384.","journal-title":"EJHaem"},{"key":"3727_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/gcc.22794","volume":"58","author":"JAI Thoms","year":"2019","unstructured":"Thoms JAI, Beck D, Pimanda JE. Transcriptional networks in acute myeloid leukemia. Genes Chromosomes Cancer. 2019;58:859\u201374.","journal-title":"Genes Chromosomes Cancer"},{"key":"3727_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.stem.2008.06.002","volume":"3","author":"S Goyama","year":"2008","unstructured":"Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell. 2008;3:207\u201320.","journal-title":"Cell Stem Cell"},{"key":"3727_CR4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1084\/jem.20110447","volume":"208","author":"K Kataoka","year":"2011","unstructured":"Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, et al. Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med. 2011;208:2403\u201316.","journal-title":"J Exp Med"},{"key":"3727_CR5","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00277-019-03774-z","volume":"98","author":"X Wu","year":"2019","unstructured":"Wu X, Wang H, Deng J, Zheng X, Ling Y, Gong Y. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Ann Hematol. 2019;98:2485\u201396.","journal-title":"Ann Hematol"},{"key":"3727_CR6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bcmd.2007.07.012","volume":"40","author":"L Laricchia-Robbio","year":"2008","unstructured":"Laricchia-Robbio L, Nucifora G. Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis. 2008;40:141\u20137.","journal-title":"Blood Cells Mol Dis"},{"key":"3727_CR7","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/leu.2012.355","volume":"27","author":"OS Kustikova","year":"2013","unstructured":"Kustikova OS, Schwarzer A, Stahlhut M, Brugman MH, Neumann T, Yang M, et al. Activation of Evi1 inhibits cell cycle progression and differentiation of hematopoietic progenitor cells. Leukemia. 2013;27:1127\u201338.","journal-title":"Leukemia"},{"key":"3727_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1172\/JCI21716","volume":"114","author":"S Buonamici","year":"2004","unstructured":"Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L, et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Investig. 2004;114:713\u20139.","journal-title":"J Clin Investig"},{"key":"3727_CR9","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1182\/blood-2009-12-261602","volume":"117","author":"A Yoshimi","year":"2011","unstructured":"Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, et al. Evi1 represses PTEN expression and activates PI3K\/AKT\/mTOR via interactions with polycomb proteins. Blood. 2011;117:3617\u201328.","journal-title":"Blood"},{"key":"3727_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/27945","volume":"394","author":"M Kurokawa","year":"1998","unstructured":"Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S, et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature. 1998;394:92\u20136.","journal-title":"Nature"},{"key":"3727_CR11","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.4049\/jimmunol.1103527","volume":"188","author":"X Xu","year":"2012","unstructured":"Xu X, Woo CH, Steere RR, Lee BC, Huang Y, Wu J, et al. EVI1 acts as an inducible negative-feedback regulator of NF-kappaB by inhibiting p65 acetylation. J Immunol. 2012;188:6371\u201380.","journal-title":"J Immunol"},{"key":"3727_CR12","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1182\/bloodadvances.2022008018","volume":"7","author":"Y Masamoto","year":"2023","unstructured":"Masamoto Y, Chiba A, Mizuno H, Hino T, Hayashida H, Sato T, et al. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment. Blood Adv. 2023;7:1577\u201393.","journal-title":"Blood Adv"},{"key":"3727_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccr.2014.02.008","volume":"25","author":"H Yamazaki","year":"2014","unstructured":"Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, et al. A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell. 2014;25:415\u201327.","journal-title":"Cancer Cell"},{"key":"3727_CR14","doi-asserted-by":"publisher","first-page":"2868","DOI":"10.1158\/2159-8290.CD-20-1793","volume":"11","author":"L Smeenk","year":"2021","unstructured":"Smeenk L, Ottema S, Mulet-Lazaro R, Ebert A, Havermans M, Varea AA, et al. Selective requirement of MYB for oncogenic hyperactivation of a translocated enhancer in leukemia. Cancer Discov. 2021;11:2868\u201383.","journal-title":"Cancer Discov"},{"key":"3727_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25862-3","volume":"12","author":"S Ottema","year":"2021","unstructured":"Ottema S, Mulet-Lazaro R, Erpelinck-Verschueren C, van Herk S, Havermans M, Arricibita Varea A, et al. The leukemic oncogene EVI1 hijacks a MYC super-enhancer by CTCF-facilitated loops. Nat Commun. 2021;12:5679.","journal-title":"Nat Commun"},{"key":"3727_CR16","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood.V81.4.883.883","volume":"81","author":"G Nucifora","year":"1993","unstructured":"Nucifora G, Birn DJ, Espinosa R, Erickson P, LeBeau MM, Roulston D, et al. Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood. 1993;81:2728\u201334.","journal-title":"Blood"},{"key":"3727_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1182\/blood.V88.2.682.bloodjournal882682","volume":"88","author":"SD Raynaud","year":"1996","unstructured":"Raynaud SD, Baens M, Grosgeorge J, Rodgers K, Reid CD, Dainton M, et al. Fluorescence in situ hybridization analysis of t(3; 12)(q26; p13): a recurring chromosomal abnormality involving the TEL gene (ETV6) in myelodysplastic syndromes. Blood. 1996;88:682\u20139.","journal-title":"Blood"},{"key":"3727_CR18","doi-asserted-by":"publisher","first-page":"6304","DOI":"10.1182\/blood-2009-07-234310","volume":"117","author":"S Arai","year":"2011","unstructured":"Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, et al. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood. 2011;117:6304\u201314.","journal-title":"Blood"},{"key":"3727_CR19","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2009.26.0646","volume":"28","author":"S Gr\u00f6schel","year":"2010","unstructured":"Gr\u00f6schel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol. 2010;28:2101\u20137.","journal-title":"J Clin Oncol"},{"key":"3727_CR20","doi-asserted-by":"publisher","first-page":"458","DOI":"10.3390\/cancers15020458","volume":"15","author":"Z Tang","year":"2023","unstructured":"Tang Z, Wang W, Yang S, El Achi H, Fang H, Nahmod KA. et al. 3q26.2\/MECOM rearrangements by pericentric Inv(3): diagnostic challenges and clinicopathologic features. Cancers. 2023;15:458","journal-title":"Cancers"},{"key":"3727_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.12659\/MSM.905903","volume":"24","author":"YZ Qin","year":"2018","unstructured":"Qin YZ, Zhao T, Zhu HH, Wang J, Jia JS, Lai YY, et al. High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy. Med Sci Monit. 2018;24:758\u201367.","journal-title":"Med Sci Monit"},{"key":"3727_CR22","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1038\/onc.2012.222","volume":"32","author":"M Maicas","year":"2013","unstructured":"Maicas M, Vazquez I, Vicente C, Garcia-Sanchez MA, Marcotegui N, Urquiza L, et al. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription. Oncogene. 2013;32:2069\u201378.","journal-title":"Oncogene"},{"key":"3727_CR23","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.bbrc.2016.11.146","volume":"482","author":"N Manachai","year":"2017","unstructured":"Manachai N, Saito Y, Nakahata S, Bahirvani AG, Osato M, Morishita K. Activation of EVI1 transcription by the LEF1\/\u03b2-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia. Biochem Biophys Res Commun. 2017;482:994\u20131000.","journal-title":"Biochem Biophys Res Commun"},{"key":"3727_CR24","first-page":"1217","volume":"22","author":"M Unoki","year":"2003","unstructured":"Unoki M, Okutsu J, Nakamura Y. Identification of a novel human gene, ZFP91, involved in acute myelogenous leukemia. Int J Oncol. 2003;22:1217\u201323.","journal-title":"Int J Oncol"},{"key":"3727_CR25","doi-asserted-by":"publisher","first-page":"30539","DOI":"10.1074\/jbc.M110.129551","volume":"285","author":"X Jin","year":"2010","unstructured":"Jin X, Jin HR, Jung HS, Lee SJ, Lee JH, Lee JJ. An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination. J Biol Chem. 2010;285:30539\u201347.","journal-title":"J Biol Chem"},{"key":"3727_CR26","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1182\/blood.2021014701","volume":"139","author":"W Wu","year":"2022","unstructured":"Wu W, Nelson GM, Koch R, Donovan KA, Nowak RP, Heavican-Foral TB, et al. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. Blood. 2022;139:2024\u201337.","journal-title":"Blood"},{"key":"3727_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.7150\/ijms.67436","volume":"19","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zhong L, Dan W, Chu X, Liu C, Luo X, et al. ZFP91 promotes cell proliferation and inhibits cell apoptosis in AML via inhibiting the proteasome-dependent degradation of RIP1. Int J Med Sci. 2022;19:274\u201385.","journal-title":"Int J Med Sci"},{"key":"3727_CR28","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1111\/bph.14493","volume":"175","author":"C Mi","year":"2018","unstructured":"Mi C, Wang Z, Li MY, Zhang ZH, Ma J, Jin X. Zinc finger protein 91 positively regulates the production of IL-1\u03b2 in macrophages by activation of MAPKs and non-canonical caspase-8 inflammasome. Br J Pharmacol. 2018;175:4338\u201352.","journal-title":"Br J Pharmacol"},{"key":"3727_CR29","doi-asserted-by":"publisher","first-page":"36551","DOI":"10.18632\/oncotarget.9070","volume":"7","author":"J Ma","year":"2016","unstructured":"Ma J, Mi C, Wang KS, Lee JJ, Jin X. Zinc finger protein 91 (ZFP91) activates HIF-1\u03b1 via NF-\u03baB\/p65 to promote proliferation and tumorigenesis of colon cancer. Oncotarget. 2016;7:36551\u201362.","journal-title":"Oncotarget"},{"key":"3727_CR30","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783\u20134.","journal-title":"Nat Methods"},{"key":"3727_CR31","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, et al. Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening. Nat Protoc. 2017;12:828\u201363.","journal-title":"Nat Protoc"},{"key":"3727_CR32","doi-asserted-by":"crossref","unstructured":"Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.","DOI":"10.1186\/gb-2002-3-7-research0034"},{"key":"3727_CR33","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1023\/B:BILE.0000019559.84305.47","volume":"26","author":"MW Pfaffl","year":"2004","unstructured":"Pfaffl MW, Tichopad A, Prgomet C, Neuvians TP. Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: bestKeeper-excel-based tool using pair-wise correlations. Biotechnol Lett. 2004;26:509\u201315.","journal-title":"Biotechnol Lett"},{"key":"3727_CR34","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41596-022-00692-9","volume":"17","author":"FC Grandi","year":"2022","unstructured":"Grandi FC, Modi H, Kampman L, Corces MR. Chromatin accessibility profiling by ATAC-seq. Nat Protoc. 2022;17:1518\u201352.","journal-title":"Nat Protoc"},{"key":"3727_CR35","first-page":"93","volume":"6","author":"S Fichelson","year":"1992","unstructured":"Fichelson S, Dreyfus F, Berger R, Melle J, Bastard C, Miclea JM, et al. Evi-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia. 1992;6:93\u201399.","journal-title":"Leukemia"},{"key":"3727_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0145-2126(00)00125-9","volume":"25","author":"S Naumann","year":"2001","unstructured":"Naumann S, Reutzel D, Speicher M, Decker HJ. Complete karyotype characterization of the K562 cell line by combined application of G-banding, multiplex-fluorescence in situ hybridization, fluorescence in situ hybridization, and comparative genomic hybridization. Leuk Res. 2001;25:313\u201322.","journal-title":"Leuk Res"},{"key":"3727_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/emph\/eot020","volume":"2013","author":"RN Mackinnon","year":"2013","unstructured":"Mackinnon RN, Wall M, Zordan A, Nutalapati S, Mercer B, Peverall J, et al. Genome organization and the role of centromeres in evolution of the erythroleukaemia cell line HEL. Evol Med Public Health. 2013;2013:225\u201340.","journal-title":"Evol Med Public Health"},{"key":"3727_CR38","doi-asserted-by":"publisher","first-page":"e1306","DOI":"10.1371\/journal.pone.0001306","volume":"2","author":"K Iwamoto","year":"2007","unstructured":"Iwamoto K, Bundo M, Ueda J, Nakano Y, Ukai W, Hashimoto E, et al. Detection of chromosomal structural alterations in single cells by SNP arrays: a systematic survey of amplification bias and optimized workflow. PLoS ONE. 2007;2:e1306.","journal-title":"PLoS ONE"},{"key":"3727_CR39","doi-asserted-by":"publisher","first-page":"111922","DOI":"10.18632\/oncotarget.22952","volume":"8","author":"C Zhao","year":"2017","unstructured":"Zhao C, Wang Q, Wang B, Sun Q, He Z, Hong J, et al. IGF-1 induces the epithelial-mesenchymal transition via Stat5 in hepatocellular carcinoma. Oncotarget. 2017;8:111922\u201330.","journal-title":"Oncotarget"},{"key":"3727_CR40","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.2147\/OTT.S195703","volume":"12","author":"B Li","year":"2019","unstructured":"Li B, Shen W, Peng H, Li Y, Chen F, Zheng L, et al. Fibronectin 1 promotes melanoma proliferation and metastasis by inhibiting apoptosis and regulating EMT. Onco Targets Ther. 2019;12:3207\u201321.","journal-title":"Onco Targets Ther"},{"key":"3727_CR41","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.7150\/jca.30223","volume":"10","author":"L Yang","year":"2019","unstructured":"Yang L, Wang L, Yang Z, Jin H, Zou Q, Zhan Q, et al. Up-regulation of EMT-related gene VCAN by NPM1 mutant-driven TGF-\u03b2\/cPML signalling promotes leukemia cell invasion. J Cancer. 2019;10:6570\u201383.","journal-title":"J Cancer"},{"key":"3727_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ccell.2016.05.011","volume":"30","author":"V Stavropoulou","year":"2016","unstructured":"Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-related genes linked to poor outcome. Cancer Cell. 2016;30:43\u201358.","journal-title":"Cancer Cell"},{"key":"3727_CR43","first-page":"56","volume":"41","author":"DE Tang","year":"2020","unstructured":"Tang DE, Dai Y, Xu Y, Lin LW, Liu DZ, Hong XP, et al. The ubiquitinase ZFP91 promotes tumor cell survival and confers chemoresistance through FOXA1 destabilization. Carcinogenesis. 2020;41:56\u201366.","journal-title":"Carcinogenesis"},{"key":"3727_CR44","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2014.11.021","volume":"159","author":"SS Rao","year":"2014","unstructured":"Rao SS, Huntley MH, Durand NC, Stamenova EK, Bochkov ID, Robinson JT, et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell. 2014;159:1665\u201380.","journal-title":"Cell"},{"key":"3727_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-018-1519-9","volume":"19","author":"Y Wang","year":"2018","unstructured":"Wang Y, Song F, Zhang B, Zhang L, Xu J, Kuang D, et al. The 3D Genome Browser: a web-based browser for visualizing 3D genome organization and long-range chromatin interactions. Genome Biol. 2018;19:151.","journal-title":"Genome Biol"},{"key":"3727_CR46","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/bjh.19322","volume":"204","author":"HL Ng","year":"2024","unstructured":"Ng HL, Robinson ME, May PC, Innes AJ, Hiemeyer C, Feldhahn N. Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells. Br J Haematol. 2024;204:945\u201358.","journal-title":"Br J Haematol"},{"key":"3727_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06208-y","volume":"9","author":"E Ayoub","year":"2018","unstructured":"Ayoub E, Wilson MP, McGrath KE, Li AJ, Frisch BJ, Palis J, et al. EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription. Nat Commun. 2018;9:4239.","journal-title":"Nat Commun"},{"key":"3727_CR48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1182\/blood.2022016592","volume":"141","author":"J Schmoellerl","year":"2022","unstructured":"Schmoellerl J, Barbosa IAM, Minnich M, Andersch F, Smeenk L, Havermans M. et al. EVI1 drives leukemogenesis through aberrant ERG activation. Blood. 2022;141:453\u201366.","journal-title":"Blood"},{"key":"3727_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05370-7","volume":"9","author":"D Elster","year":"2018","unstructured":"Elster D, Tollot M, Schlegelmilch K, Ori A, Rosenwald A, Sahai E, et al. TRPS1 shapes YAP\/TEAD-dependent transcription in breast cancer cells. Nat Commun. 2018;9:3115.","journal-title":"Nat Commun"},{"key":"3727_CR50","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9046","volume":"8","author":"A Yamamoto","year":"2020","unstructured":"Yamamoto A, Kurata M, Onishi I, Sugita K, Matsumura M, Ishibashi S, et al. CRISPR screening identifies M1AP as a new MYC regulator with a promoter-reporter system. PeerJ. 2020;8:e9046.","journal-title":"PeerJ"},{"key":"3727_CR51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.7554\/eLife.57858","volume":"9","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhang Y, Zhou X, Wright S, Hyle J, Zhao L. et al. Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR\/Cas9 screen. eLife. 2020;9:453\u201366.","journal-title":"eLife"},{"key":"3727_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46285-w","volume":"15","author":"S Spisak","year":"2024","unstructured":"Spisak S, Chen D, Likasitwatanakul P, Doan P, Li Z, Bala P, et al. Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system. Nat Commun. 2024;15:2230.","journal-title":"Nat Commun"},{"key":"3727_CR53","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1021\/acs.jmedchem.0c01897","volume":"64","author":"M Hanafi","year":"2021","unstructured":"Hanafi M, Chen X, Neamati N. Discovery of a napabucasin PROTAC as an effective degrader of the E3 ligase ZFP91. J Med Chem. 2021;64:1626\u201348.","journal-title":"J Med Chem"},{"key":"3727_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15398","volume":"8","author":"J An","year":"2017","unstructured":"An J, Ponthier CM, Sack R, Seebacher J, Stadler MB, Donovan KA, et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4. Nat Commun. 2017;8:15398.","journal-title":"Nat Commun"},{"key":"3727_CR55","doi-asserted-by":"publisher","first-page":"8558","DOI":"10.7150\/thno.44873","volume":"10","author":"D Chen","year":"2020","unstructured":"Chen D, Wang Y, Lu R, Jiang X, Chen X, Meng N, et al. E3 ligase ZFP91 inhibits hepatocellular carcinoma metabolism reprogramming by regulating PKM splicing. Theranostics. 2020;10:8558\u201372.","journal-title":"Theranostics"},{"key":"3727_CR56","first-page":"354","volume":"50","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Zhang J, Ye Z, Peng P, Lan X, Xie L, et al. Evi-1 influence on clinical progress of colorectal cancer patients. Ann Clin Lab Sci. 2020;50:354\u201360.","journal-title":"Ann Clin Lab Sci"},{"key":"3727_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcab023","volume":"3","author":"HR Kim","year":"2021","unstructured":"Kim HR, Yim J, Yoo HB, Lee SE, Oh S, Jung S, et al. EVI1 activates tumor-promoting transcriptional enhancers in pancreatic cancer. NAR Cancer. 2021;3:zcab023.","journal-title":"NAR Cancer"},{"key":"3727_CR58","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/cas.12694","volume":"106","author":"K Yasui","year":"2015","unstructured":"Yasui K, Konishi C, Gen Y, Endo M, Dohi O, Tomie A, et al. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-\u03b2-mediated growth inhibition in hepatocellular carcinoma. Cancer Sci. 2015;106:929\u201337.","journal-title":"Cancer Sci"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03727-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:02:47Z","timestamp":1780956167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03727-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":58,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026,6,30]]}},"alternative-id":["3727"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03727-7","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"5 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.M. and M.K. have received honoraria from Bristol Myers Squibb. The other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experiments have been performed in accordance with the relevant guidelines and regulations. This research article does not include any studies with live vertebrates or humans.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}